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Abstract
The adhesin pertactin (Prn) is one of the major virulence factors of Bordetella pertussis, the etiological agent of whooping
cough. However, a significant prevalence of Prn-deficient (Prn
2) B. pertussis was observed in Japan. The Prn
2 isolate was
first discovered in 1997, and 33 (27%) Prn
2 isolates were identified among 121 B. pertussis isolates collected from 1990 to
2009. Sequence analysis revealed that all the Prn
2 isolates harbor exclusively the vaccine-type prn1 allele and that loss of
Prn expression is caused by 2 different mutations: an 84-bp deletion of the prn signal sequence (prn1DSS, n=24) and an
IS481 insertion in prn1 (prn1::IS481, n=9). The frequency of Prn
2 isolates, notably those harboring prn1DSS, significantly
increased since the early 2000s, and Prn
2 isolates were subsequently found nationwide. Multilocus variable-number tandem
repeat analysis (MLVA) revealed that 24 (73%) of 33 Prn
2 isolates belong to MLVA-186, and 6 and 3 Prn
2 isolates belong to
MLVA-194 and MLVA-226, respectively. The 3 MLVA types are phylogenetically closely related, suggesting that the 2 Prn
2
clinical strains (harboring prn1DSS and prn1::IS481) have clonally expanded in Japan. Growth competition assays in vitro also
demonstrated that Prn
2 isolates have a higher growth potential than the Prn
+ back-mutants from which they were derived.
Our observations suggested that human host factors (genetic factors and immune status) that select for Prn
2 strains have
arisen and that Prn expression is not essential for fitness under these conditions.
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Introduction
Bordetella pertussis is the causative agent of pertussis or whooping
cough, a highly contagious disease of the human upper respiratory
tract. Adolescents and adults are its primary reservoir and play a
crucial role in the transmission of the microbe to infants and
unvaccinated children [1,2]. Immunization is the most effective
method for the prevention and control of pertussis. In Japan,
acellular pertussis (aP) vaccines were introduced in 1981 and
pertussis has been controlled by means of a schedule of three
primary doses and a single booster dose at ages 3, 4, 5, and 18–23
months. The vaccine coverage with three primary does has been
$90%.
B. pertussis produces several virulence factors that contribute to
its adherence to the respiratory ciliate epithelium. The virulence
factors pertussis toxin (PT) and filamentous haemagglutinin (FHA)
are critical antigens responsible for inducing immunity to B.
pertussis and are included as major antigens in aP vaccines. Some
aP vaccines include either the virulence factor pertactin (Prn) and/
or fimbriae (Fim) as additional antigen(s). Among four currently
used Japanese aP vaccines, two vaccines contain Prn (5–7.5 mg per
0.5 ml dose) and Fim2 (1 mg/dose), and others do not contain both
Prn and Fim2 [3]. In contrast, aP vaccines widely used in Europe
and the USA contain from 3 to 8 mg per dose of Prn: Infanrix,
8 mg; DAPTACEL, 3 mg. The three-component aP vaccine
containing PT, FHA, and Prn is more effective than the two-
component aP vaccine consisting of only PT and FHA [4,5]. In
vaccine efficacy trials, the anti-Prn antibody level correlates with
clinical protection, suggesting an important role for Prn in
immunity [6]. In vitro studies also show that anti-Prn antibody
is crucial for opsonophagocytosis [7].
Prn belongs to the type V autotransporter family whose
members undergo autoproteolytic processing; mature Prn is a
69-kDa protein that is attached to the bacterial cell surface
[8,9,10]. This protein contains an RGD (Arg-Gly-Asp) motif,
which is implicated in ligand-receptor interactions in eukaryotes
[11]. Prn is considered to function as an adhesin that can bind
human epithelial cells; however, the host receptor for Prn has not
been identified. Besides its potential role as an adhesin, Bordetella
bronchiseptica Prn has been shown to function as a phage receptor
[12,13]. During the last decade, Prn polymorphism has been
described among B. pertussis strains circulating worldwide. Prn
variation is mainly limited to 2 regions, designated as region 1 (R1)
and region 2 (R2), which are composed of the repeat motifs
(GGXXP)n and (PQP)n, respectively [14]. Most variations are
found in R1, which is located adjacent to an RGD motif. Thirteen
Prn variants have been identified so far [15,16]. In Japan, Prn1
and Prn2 variants currently predominate; however, the vaccine-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31985type Prn1 has been gradually replaced with the nonvaccine-type
Prn2 since the mid-1990s [17]. A recent study shows that the
ability of B. pertussis strains to colonize mouse lung decreases in the
order Prn1.Prn2 and Prn3 [18].
B. pertussis Prn
2 isolates are present in Europe [19,20]. The
Prn
2 isolates were collected in Italy (n=1) and France (n=4), and
this phenotype is due to the deletion of prn or insertion of the
IS481 element. The IS481 is present in multiple copies in the B.
pertussis chromosome, causing frequent chromosomal rearrange-
ments and deletions [21,22]. The emerging Prn
2 strains raise the
possibility that the prevalence of Prn
2 strains reduces the efficacy
of aP vaccines containing Prn. Here, we identified the significant
prevalence of Prn
2 strains recently circulating in Japan. To obtain
detailed insights into these strains with respect to their genetic,
temporal, and geographical characteristics, we performed se-
quence analysis and multilocus variable-number tandem repeat
analysis (MLVA). Using an in vitro growth competition assay, we
attempted to gain insights into the biological mechanisms
responsible for the prevalence of Prn
2 strains.
Results
Identification of Prn
2 isolates
B. pertussis Prn expression was analyzed by immunoblotting with
anti-Prn1 antiserum. Figure 1 shows a representative blot of 6 Prn-
positiveand 4 negative isolates. Total 33 Prn
2 isolates were identified
among 121 B. pertussis isolates collected in 1990–2009 in Japan, which
we acquired from the National Institute of Infectious Diseases (NIID),
Japan. Interestingly, all Prn
2 isolates harbor vaccine-type prn1 and
ptxA2 alleles. The expression of other virulence factors PT, FHA, and
Fim3 was detected in the recent Prn
2 isolates (collected in 2005–
2009) by immunoblotting and serotyping. Detailed information on
these 121 isolates is listed in Table S1.
Sequence analysis of Prn
2 isolates
To investigate the molecular basis for the loss of Prn expression
in Prn
2 isolates, we sequenced the Prn gene of all 33 Prn
2 isolates.
Two independent mutations were detected, which had caused the
loss of Prn1: a deletion of the prn1 signal sequence (prn1DSS) and
an IS481 insertion, prn1::IS481 (Figure 2). The prn1 signal
sequence, which plays an important role in localizing Prn to the
B. pertussis outer cell membrane, was deleted in 24 (73%) out of 33
Prn
2 isolates. All 24 isolates harboring prn1DSS had the same 84-
bp deletion, resulting in the deletion of 28 amino acid residues
(Val
9–Trp
36) (Figure 2A). Secondary structure analysis also
showed that the deleted DNA sequence is predicted to form a
hairpin-loop structure (Figure S1). In contrast, 9 (27%) of 33 Prn
2
isolates were shown to contain the IS481 insertion in prn1. Eight
IS481 sequences were specifically inserted in the 59–39 orientation
between a 6-bp direct repeat (ACTAGG, 1593–1598 bp), and 1
was oriented in the opposite direction (Figure 2B).
Temporal and geographical characterization in Prn
2
isolates
Figure 3 shows the temporal trend of the frequency of Prn
2
strains among 121 B. pertussis isolates according to the year of
collection. The frequencies of Prn
2 isolate harboring prn1DSS
were 0, 0, 27 and 25% in the periods 1990–1994, 1995–1999,
2000–2004 and 2005–2009, respectively. In contrast, the frequen-
cies of Prn
2 isolates harboring prn1::IS481 were 0, 5, 11 and 7% in
1990–1994, 1995–1999, 2000–2004 and 2005–2009, respectively.
Notably, the total percentage of the Prn
2 isolates significantly
increased from the 2000s, i.e., 0% in 1990–1994, 5% in 1995–
1999, 38% in 2000–2004 and 32% in 2005–2009.
During 1990 to 2000, 5 Prn
2 isolates (prn1DSS, 4 isolates;
prn1::IS481, 1 isolate) were collected only in the Kanto district.
Thereafter, Prn
2 isolates were collected in several areas during
Figure 1. Prn expression in B. pertussis clinical isolates. The isolates harboring prn2 allele (BP157, BP159, BP162, BP228, and BP235) and prn1
allele (BP155, BP156, BP232, BP233, and BP243) were cultured on CSM plates. Total protein (10 mg) extracted from the bacterial cells was separated by
SDS-PAGE followed by CBB R-250 staining (left panel). Immunoblots (1 mg protein/lane) were incubated with anti-Prn1, anti-PT or anti-FHA antiserum
(right panel). Ten ng of purified Prn1, PT, or FHA and total protein (1 mg) from B. pertussis Tohama were run on the gel as positive controls.
doi:10.1371/journal.pone.0031985.g001
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2
isolates harboring prn1DSS were collected from Tohoku, Kanto,
Chubu, Kinki, and Kyushu districts, and 8 Prn
2 isolates harboring
prn1::IS481 were collected from Kanto, Chubu, Kinki, Shikoku,
and Kyushu. These findings indicate that Prn
2 isolates were
present nationwide since 2000.
Molecular epidemiology of Prn
2 isolates
Thirty-three Prn
2 and 88 Prn
+ isolates collected by the NIID
between 1990 and 2009 were subjected to MLVA. Among the 121
isolates, 33 different MLVA types were identified, of which 10
were novel (MLVA-223 to -227, -229, -230, -233, -234, and -248)
(Figure 5 and Table S1). Twenty-six of these MLVA types were
present at low frequencies (each, #2% of all isolates). Thirty-three
Prn
2 isolates belonged to only 3 MLVA types; 24 isolates (73%)
were MLVA-186, 6 isolates (18%) were MLVA-194, and 3 isolates
(9%) were MLVA-226. MLVA-186 was the predominant type
(frequency, 35% of all isolates), whereas MLVA-194 and MLVA-
226 were minor (frequency, 5% and 2%, respectively). The
3 MLVA types were closely related phylogenetically. When
categorized by their mutations, 24 Prn
2 isolates harboring prnDSS
Figure 2. Molecular mechanisms of loss of Prn expression. (A) Deletion of the Prn signal sequence (prn1DSS). Prn
2 isolates (n=24) have an
84-bp deletion, resulting in a 28-amino acid deletion (Val
9 to Trp
36) in the N-terminal region. (B) IS481 insertion mutation in Prn1 gene (prn1::IS481).
Eight Prn
2 isolates have an IS481 insertion in the forward direction at the 6-bp direct repeats (ACTAGG, 1593–1598 bp) of prn1, and 1 isolate had the
insertion in the reverse.
doi:10.1371/journal.pone.0031985.g002
Figure 3. Temporal trend of the occurrence of Prn
2 isolates in
Japan. The frequencies of Prn
2 isolates harboring prn1DSS and
prn1::IS481 were based on 121 B. pertussis isolates collected during
1990–2009. Prn
+ indicates Prn-expressing isolate.
doi:10.1371/journal.pone.0031985.g003
Figure 4. Geographical distribution of Prn
2 isolates in Japan
during 2001–2009. Blue and red circles indicate Prn
2 isolates
harboring prn1DSS and prn1::IS481, respectively. Numbers of isolates
tested are indicated in parentheses.
doi:10.1371/journal.pone.0031985.g004
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226 (n=2); 9 Prn
2 isolates harboring prn1::IS481 belonged to
MLVA-186 (n=8) and MLVA-226 (n=1). Thus, MLVA-186 and
MLVA-226 were common to both the Prn
2 isolates, whereas only
the Prn
2 isolate harboring prn1DSS was typed as MLVA-194.
Growth advantage of Prn
2 isolates
We investigated the growth advantage of Prn
2 isolates by an in
vitro growth competition assay. For this purpose, we constructed 2
Prn
+ back-mutants (Prn
+-BP59Sm
r and Prn
+-BP202Sm
r) that were
derived from B. pertussis isolates BP59 (prn1DSS) and BP202
(prn1::IS481), which expressed Prn at a level similar to that of the
B. pertussis vaccine strain Tohama (Figure S2). B. pertussis Tohama
produced Prn1 at levels similar to those of other Prn
+ isolates
(Figure 1), indicating that the Prn
+ back-mutants expressed Prn1 at
the same levels as those of naturally occurring Prn
+ isolates. The
Prn
+ back-mutants also produced PT and FHA at levels equivalent
to their parental strains. Moreover, the expression of Fim2 and/or
Fim3 was confirmed in the Prn
+ back-mutants by serotyping (data
not shown).
Figure 6 shows the growth characteristics of the Prn
2 strain.
When the Prn
+-BP202Sm
r back-mutant was co-cultured with its
parent, Prn
2-BP202Sm
r, the percentage of Prn
2-BP202Sm
r cells
increased markedly with time and then reached 100% after 72 h.
Similarly, the percentage of Prn
2-BP59Sm
r increased, reaching
71% and 78% at 72 and 144 h, respectively. These results indicate
that Prn
2 strains have higher growth rates in vitro than their Prn
+
back-mutants. Surprisingly, when the Prn
2 and Prn
+ strains were
individually cultured in mSS broth, no significant differences were
observed in their growth rates (data not shown). Furthermore, no
revertant Prn
2 strains arising from the Prn
+ back-mutants were
observed under the individual culture conditions.
Discussion
Here, we demonstrate that B. pertussis Prn
2 isolates, generated
by 2 different mutations, prnDSS and prn::IS481, have significantly
increased in Japan since the early 2000s. The emerging Prn
2
isolates were found nationwide in the 2000s and were found to
specifically harbor the vaccine-type prn1 allele. The rate of Prn
2
isolation from 2005 to 2009 was 32% (18/57). We believe that this
rate is accurate because we investigated all of the isolates (collected
in 2005–2009) present in the NIID strain collections except for
epidemiologically related cases. Recently, Prn
2 mutants were also
isolated in France at a rate of 5.6% [20], which is significantly
lower than for Japan. Taken together, our findings confirm the
high prevalence of Prn
2 strains in the Japanese B. pertussis
population and raise the question of the pathogenic role of Prn1 in
B. pertussis infections.
MLVA analysis revealed that various Prn
2 isolates have high
genetic similarity. The Prn
2 isolates are mainly of the MLVA type
186. The MLVA type has been found in specific countries, Japan
and Hong Kong, China [23]. The data on the geographic
distribution of Prn
2 isolates lend support to our hypothesis that the
Prn
2 isolate harboring prn1DSS or prn1::IS481 has clonally
expanded. Interestingly, 3 of 4 French Prn
2 isolates have an
Figure 5. Minimum spanning tree of MLVA of Prn
2 and Prn
+ isolates. Total 121 B. pertussis isolates, collected during 1990–2009 in Japan,
were subjected to MLVA: Prn
2 isolate harboring prn1DSS, 24 isolates; Prn
2 isolate harboring prn1::IS481, 9 isolates; Prn
+ isolate, 88 isolates. Each circle
in the tree represents a different MLVA type with the MLVA type number. The distance between neighboring genotypes is expressed as the similarity
value. Prn
2 isolates belong to MLVA-186, -194, and -226.
doi:10.1371/journal.pone.0031985.g005
Figure 6. Population dynamics of Prn
2 strains in in vitro
growth competition assay. Prn
+ back-mutants and parental Prn
2
strains were mixed in the ratio 4:1 (Prn
+-BP59Sm
r versus BP59Sm
r or
Prn
+-BP202Sm
r versus BP202Sm
r) and cocultured in mSS broth at 36uC.
The bacterial cultures were collected at 0, 36, 72 and 144 h, and plated
on CSM agar plates. The representation of Prn
2 strains among 40
colonies was examined by colony-PCR. Data are means and standard
deviations from 3 independent experiments.
doi:10.1371/journal.pone.0031985.g006
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2
isolates,and the other French Prn
2 isolate has a larger prn deletion
(2.4-kbp) involving the 59-upstream region and signal sequence
[20]. Unlike Japanese Prn
2 isolates, all French Prn
2 isolates
harbor nonvaccine-type prn2 alleles, indicating that the Japanese
Prn
2 isolates are genetically distinguishable from the French Prn
2
isolates.
Japanese Prn
2 isolates harboring prn1DSS had an 84-bp
deletion in the prn signal sequence. The deleted DNA sequence
is predicted to form a hairpin loop structure, suggesting that the
DNA loop might be excised from the prn1 by DNA repair
enzyme(s) (Figure S1). Although the deleted sequence does not
affect the translational reading frame of Prn1 gene, a truncated
Prn1 precursor was not detected in the Prn
2 isolates (Figure 1).
Interestingly, in vitro transcriptional-translation analysis revealed
that the prn1DSS gene could be transcribed and translated as a
truncated Prn1 precursor (data not shown). This suggests
immediate degradation of truncated Prn1 in the bacterial cell. In
contrast, Prn
2 isolates harboring prn1::IS481 were disrupted by an
IS481-insertion at a 6-bp direct repeat (ACTAGG, 1593–1598 bp)
in prn1. The direct repeats in prn1 conform to the recognition
sequence of IS481, NCTAGN [24]. IS481 is present in multiple
copies in the B. pertussis chromosome and the number of lost genes
increased with time by IS481-dependent rearrangement [22,25].
Taken together with information published on French Prn
2
isolates, 3 different mechanisms, IS481 insertion and 2 prn
deletions (84-bp and 2.4-kb), have contributed to the loss of Prn
expression in B. pertussis. These gene disruptions strongly suggest
that human host factors (genetic factors and immune status) that
select for Prn
2 strains have arisen.
Prn’s adhesin properties have been investigated both in vitro
and in vivo [26,27,28,29]. A recent study showed that B. pertussis
Prn
2 mutants colonized less well than Prn
+ strains in mice [18]. It
is also known that Prn prevents either bacterial adherence or
internalization or both, to human monocyte-derived dendritic cells
[30] and that it also plays a role in resistance to neutrophil-
mediated clearance [31]. Further, B. bronchiseptica Prn is required
for optimal colonization of the swine respiratory tract [32]. Prn
may therefore play a crucial role in bacterial adhesion and in
survival and colonization in humans. However, here we have
discovered a high prevalence of Prn
2 isolates in recent B. pertussis
populations in Japan. This observation strongly suggests that loss
of Prn does not significantly reduce bacterial fitness in the present
environment. Prn is highly conserved among the Bordetella species.
Surprisingly, Prn
2 isolates of the human pathogen Bordetella
parapertussis have also been found recently in France [33]. This
finding supports our hypothesis that the role of Prn in fitness (or
transmission) has diminished in some hosts.
We demonstrate here that Prn
2 strains have a higher growth
potential than their Prn
+ back-mutants in vitro (Figure 6). The
increased growth advantage of Prn
2 strains provides knowledge
about their biological properties. The most likely explanation for
prevalence of Prn
2 strains is vaccine-driven selection. Prn is an
important antigenic component of most current aP vaccines, and it
plays a role in eliciting protective immunity [4,6,7,34,35], leading
to the suggestion that Prn
2 strains have escaped the immune
response to Prn. The herd immunity by aP vaccines could exert
selective pressure for pathogen evolution, like the emergence of the
PT promoter (ptxP3) lineage that produces higher levels of PT
[36]. In fact, Prn1 strains might be more fit in unvaccinated than
in vaccinated populations [18]. In Japan, four currently used
vaccines are produced from B. pertussis vaccine strain Tohama; two
vaccines contain Prn1 and others do not contain it [3]. The aP
vaccines that can be used interchangeably for routine immuniza-
tion of infants have been introduced in Japan since 1981.
Subsequently, Prn1 clinical strains have been gradually replaced
by Prn2 strains since the mid-1990s [17], and Prn
2 strains
significantly increased since the early 2000s (as shown here). These
observations suggest the interesting possibility that Prn
2 strains
may have increased fitness in vaccinated populations, i.e., Prn1
strains are most affected by vaccination with aP vaccines
containing Prn1, whereas Prn2 strains producing non-vaccine
type Prn are not. However, in the present study, the vaccination
status of the majority of patients infected with Prn
2 strain was
unknown (Table S1). Thus, the relationship between Prn
2 strains
and vaccine efficacy is currently unclear. Further studies now
underway on patients’ background are needed to verify the
hypothesis.
In conclusion, Prn
2 strains have significantly increased in B.
pertussis populations since the early 2000s in Japan. B. pertussis Prn
2
strains have also been found in France, as well as among isolates of
the human pathogen B. parapertussis. These observations suggest
that Prn expression may be not essential for fitness of Bordetella
species in the recent host environment and that Prn
2 strains may
be fit in humans immunized with aP vaccines. Further analyses
and global surveillance are required to elucidate the emergence of
Prn
2 strains.
Materials and Methods
Bacterial strains
We studied 121 B. pertussis clinical isolates collected from 1990
to 2009 in Japan (Table S1). The isolates were selected from the
National Institute of Infectious Diseases (NIID) strain collections to
reflect the same temporal distribution of the prn allele [17,37].
Seventy-nine isolates harbor the vaccine-type prn1 allele, and 41
and 1 isolates harbor nonvaccine-type prn2 and prn9 allele,
respectively. All the isolates were epidemiologically unrelated
cases of pertussis. The isolates were cultured on Bordet-Gengou
agar (Difco) supplemented with 1% glycerol and 15% defibrinated
horse blood and incubated at 36uC for 2–3 days.
Immunoblotting and serotyping
B. pertussis isolates were subcultured on cyclodextrin solid
medium (CSM) [38]. Total protein was extracted from bacterial
cells with SDS-lysis buffer (62.5 mM Tris-HCl, 1% SDS, 10%
glycerol, 5% 2-mercaptoethanol, pH 6.8). Protein samples (1 mg
protein) were subjected to 10% SDS-PAGE, transferred to
nitrocellulose membranes (Bio-Rad), and incubated with anti-
Prn1, anti-FHA, or anti-PT antiserum. Antigen-antibody com-
plexes were visualized using horseradish peroxidase (HRP)-
conjugated secondary antibody (Bio-Rad) and ECL Western
Blotting Detection Reagents (GE Healthcare) and the blots imaged
using a LAS-3000 (Fujifilm, Tokyo, Japan). The anti-Prn1
antiserum was generated in mice with purified Prn1 derived from
B. pertussis strain Tohama.
Serotyping of B. pertussis isolates was performed in a microplate
agglutination assay using ati-Fim2 and anti-Fim3 monoclonal
antibodies [39]. The anti-Fim2 (NIBSC 04/154) and anti- Fim3
(NIBSC 04/156) antibodies were obtained from the National
Institute for Biological Standard and Control. B. pertussis strain
18323 expressing both Fim2 and Fim3 was used as a positive
control [40].
DNA sequencing
DNA sequencing of PCR fragments representing relevant
regions of prn was performed as described [14,41]. Sequence
reactions were carried out with a BigDyeH Terminator v3.1 Cycle
Pertactin-Deficient Bordetella pertussis
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sequenced using an ABI PRISM 3130xl Genetic Analyzer
(Applied Biosystems). The complete open reading frames of all
Prn
2 isolates (n=33) were determined.
MLVA
MLVA typing was performed as described previously [23,42].
Six variable-number tandem-repeat loci (VNTR1, 3a, 3b, 4, 5,
and 6) were amplified by PCR, and the fragments were separated
using an ABI PRISM 3130xl Genetic Analyzer with GeneScan
TM-
600LIZH (Applied Biosystems) as an internal lane size standard.
For each VNTR locus, the size of the PCR product was converted
to a number of repeat units as alleles using GeneMapper software
ver.4.0 (Applied Biosystems). Each MLVA type was assigned as
described earlier [23,43], and novel MLVA type numbers were
assigned by Dr. F. Mooi, Netherlands Centre for Infectious
Diseases Control, National Institute for Public Health and the
Environment, The Netherlands.
Minimum spanning trees were generated from the 6 MLVA loci
using the FPQuest Software (Bio-Rad). Links were generated
between MLVA types with a categorical comparison algorithm,
with the following rules in priority order: (1) Link types must have
the maximum number of single-locus variants (SLVs), (2) types
must have the maximum number of SLVs and double-locus
variants, and (3) types must have the maximum number of entries.
Generation of Prn
+ back-mutants
Two Prn
+ back-mutants (Prn
+-BP59Sm
r and Prn
+-BP202Sm
r)
were constructed from Prn
2 isolates BP59 (prn1DSS) and BP202
(prn1::IS481) by double cross-over homologous recombination,
respectively [44]. To construct the Prn
+-BP59Sm
r back-mutant, a
2.4-kbp DNA fragment (prnA) encoding the intact prn signal
sequence was amplified by PCR with attB1-sigF and attB2-sigR
primers (Table S2) using B. pertussis Tohama genomic DNA as the
template. The resulting PCR product was cloned into pDONR221
to obtain pDONR-prnA using the adaptor PCR method in the
Gateway cloning system (Invitrogen). The pDONR-prnA and
pABB-CRS2 [45] were combined to obtain pABB-prnA using the
Gateway cloning system. pABB-prnA was introduced into E. coli
SM10lpir and transconjugated into strain BP59Sm
r (streptomycin-
resistant, Sm
r). The resulting mutant was designated Prn
+-
BP59Sm
r.
To construct the Prn
+-BP202Sm
r back-mutant, a 2.3-kbp DNA
fragment (prnB) encoding intact prn gene was PCR-amplified using
attB1-ISF and attB2-ISR primers (Table S2). Plasmid pABB-prnB
was constructed from pDONR-prnB and then transconjugated
into strain BP202Sm
r via E. coli SM10lpir. The resulting mutant
was designated Prn
+-BP202Sm
r.
To confirm site-specific recombination, the prn of Prn
+ back-
mutants was sequenced, confirming that the pABB vector
sequence was entirely removed from prn of both Prn
+ back-
mutants.
In vitro growth competition assay
Prn
+ back-mutants (Prn
+-BP59Sm
r and Prn
+-BP202Sm
r) and
their parental Prn
2 strains (BP59Sm
r and BP202Sm
r) were
inoculated into modified Stainer-Scholte (mSS) broth [46], and
cultured with shaking at 36uC. After 24 h, the culture solutions
were diluted to an optical density (650 nm) of 0.2 with mSS broth.
The Prn
+ back-mutant (2.4 ml) and its parental Prn
2 strain
(0.6 ml) were mixed at the ratio 4:1 and co-cultured with shaking
at 36uC. The bacterial cultures (30 ml) were subcultured once in
fresh mSS broth (3 ml) for 72 h.
The bacterial cultures were collected at 0, 36, 72, and 144 h,
diluted with 1% casamino acid solution containing 0.6% NaCl,
pH 7.1, and plated on CSM agar plates. After incubation for 3–4
days, 40 colonies were checked for prn size by colony-PCR
performed as follows: 94uC for 2 min; 30 cycles of 98uC for 10 s,
55uC for 30 s, and 68uC for 3 min; and final incubation at 72uC
for 5 min. Primer sets, PrnF and 1053R, and PrnF and PrnR,
were used for strains BP59Sm
r (prn1DSS) and BP202Sm
r
(prn1::IS481), respectively (Table S2).
Nucleotide sequence accession number
The nucleotide sequence data reported in this study have been
deposited in the DDBJ/EMBL/GenBank nucleotide sequence
databases under accession numbers AB670735 to AB670737.
Supporting Information
Figure S1 A hairpin loop structure in the signal
sequence (SS) of Prn gene. Twenty-four Prn
2 isolates
harboring prn1DSS have an 84-bp deletion at position 26–
109 bp, corresponding to the hairpin loop. The schematic shows
a simplified map.
(TIF)
Figure S2 Expression of Prn, PT, and FHA in Prn
+ back-
mutants derived from Prn
2 isolates. Prn
+ back-mutants
(Prn
+-BP59Sm
r and Prn
+-BP202Sm
r) were constructed from
streptomycin-resistant Prn
2 isolates, BP59Sm
r (prn1DSS), and
BP202Sm
r (prn1::IS481), respectively. Total protein (1 mg) extract-
ed from the bacterial cells was subjected to SDS-PAGE and
analyzed by immunoblotting with anti-Prn1, anti-PT or anti-FHA
antiserum. Total protein (1 mg) from B. pertussis Tohama was run
on the gel as a positive control. PT-S1 indicates the S1 subunit of
PT.
(TIF)
Table S1 Characteristics of B. pertussis isolates.
(XLSX)
Table S2 PCR primers in this study.
(XLSX)
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